Stay updated on Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial
Sign up to get notified when there's something new on the Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial page.

Latest updates to the Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe study page now displays a 403 Forbidden error instead of the expected study content, indicating restricted access to the record.SummaryDifference19%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe site footer now shows Revision: v3.6.6, replacing the previous revision. This indicates a minor deployment/version label update.SummaryDifference0.1%

- Check49 days agoChange DetectedThe site revision label was updated from v3.6.4 to v3.6.5, indicating a software update to the platform. No study content or user-facing information appears to have changed.SummaryDifference0.0%

- Check64 days agoChange DetectedThe page revision was updated from v3.6.3 to v3.6.4, signaling a new version of the page and its metadata.SummaryDifference0.0%

- Check85 days agoChange DetectedThe page revision label was updated from v3.6.2 to v3.6.3, indicating a new site build; no study content or critical information appears to be altered.SummaryDifference0.0%

- Check93 days agoChange DetectedThe page's revision indicator has been updated from v3.6.0 to v3.6.2. This reflects a metadata update rather than any substantive changes to trial information or content.SummaryDifference0.0%

Stay in the know with updates to Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nal-Irinotecan & Nivolumab in Biliary Cancer Clinical Trial page.